(RTTNews) - Eliem Therapeutics Inc. (ELYM) Tuesday said its Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain or sciatica failed to achieve the primary endpoint and that program will be discontinued.
Earlier in April, the clinical-stage biotechnology company has reported the lack of separation from placebo observed in the Phase 2a clinical trial in diabetic peripheral neuropathic pain or DPNP.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
